Novel Inactivated Virus Vaccine Against Herpesviruses
- Technology Application
- Prophylactic and therapeutic vaccines against herpesviruses associated diseases.
- Detailed Technology Description
- Researchers at the University of California have developed a new and very effective method of vaccination against HSV2. The vaccine consists of a combination of inactivated herpesvirus mixed with the adjuvants monophosphoryl lipid A (MPL) and alum. The invention has been proved in animal models to afford complete protection against acute and recurrent HSV-2 genital diseases, and provided significantly higher levels of protection against both disease and virus shedding compared with another vaccine now in clinical trials.
- Supplementary Information
- Inventor: SPECTOR, Deborah, H. | MORELLO, Christopher, S. | KRAYNYAK, Kimberly, A.
Priority Number: WO2013006569A3
IPC Current: A61K0039245 | A61K0009127 | A61K003939 | A61K004748 | A61P002528 | A61P003100
Assignee Applicant: The Regents of the University of California
Title: HERPES VIRUS VACCINE AND METHODS OF USE | VACCIN CONTRE LE VIRUS DE L'HERPÈS ET PROCÉDÉS D'UTILISATION
Usefulness: HERPES VIRUS VACCINE AND METHODS OF USE | VACCIN CONTRE LE VIRUS DE L'HERPÈS ET PROCÉDÉS D'UTILISATION
Summary: The agent is useful for treating disease caused by HV infection. The disease is chosen from herpetic gingivostomatitis, herpes labialis, herpes genitalis, herpetic whitlow, herpes gladiatorum, herpesviral encephalitis, herpesviral meningitis, herpes esophagitis, herpes keratitis, Bell's palsy, Mollaret's meningitis, herpes rugbeiorum, eczema herpeticum, herpetic neuralgia, post-herpetic neuralgia and Alzheimer's disease (all claimed).
Novelty: Vaccine useful for treating disease e.g. herpetic gingivostomatitis and herpes labialis caused by herpes virus infection, comprises inactivated HV, lipopolysaccharide-derived adjuvant and aluminum-based mineral salt adjuvant
- Industry
- Biomedical
- Sub Category
- Pharmaceuticals
- Application No.
- 9555100
- Others
-
State Of Development
Inventors have validated the novel vaccine in vivo, using mouse and guinea pig models. The vaccine was able to completely protect against both acute and recurrent lesion development, and to clear the virus from the dorsal root ganglia. Ongoing studies show that further modifications to the technique produce even greater therapeutic efficacy.
Intellectual Property Info
Worldwide rights are available. Publication # WO 2013/006569 A2, Application # PCT/US2012/045290
For background information please also see case number 2006-121.
Related Materials
Morello CS, et. al., Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine. 2012 Oct 12;30(46): 6541-50.
Morello CS, et al., Immunization with Herpes Simplex Virus 2 (HSV-2) Genes plus Inactivated HSV-2 Is Highly Protective against Acute and Recurrent HSV-2 Disease. J Virol. (2011) 85(7): 3461-72.Additional Technologies by these Inventors
Tech ID/UC Case
22936/2011-325-0
Related Cases
2011-325-0
- *Abstract
-
Herpes simplex virus type 2 (HSV-2) infection is the most common cause of genital herpes, a sexually transmitted disease estimated to affect more than 500 million people worldwide. About one in six people in the United States aged between 14 and 49 years has genital herpes caused by HSV-2. In addition to causing painful recurring genital sores and emotional stress in those infected, the disease can be particularly severe in immunosuppressed patients and can cause death or brain damage in babies born to infected mothers. Antiviral drugs are being used widely to treat HSV-2, but they are ineffective at eradicating the disease. There is therefore an urgent need for a safe and effective HSV-2 vaccine.
- *IP Issue Date
- Jan 31, 2017
- *Principal Investigator
-
Name: Kimberly Kraynyak
Department:
Name: Christopher Morello
Department:
Name: Deborah Spector
Department:
- Country/Region
- USA
